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httpcense.Abstract Objective: The overall objective of this work is to study the cerebral metabolic changes
in patients with OSA and to determine the usefulness of MRS as an objective method for evaluation
of CNS impairment in these patients.
Materials and methods: This study included two groups; group1 ﬁfteen (15) patients diagnosed
with obstructive sleep apnea hypopnea syndrome, and group 2 ten (10) healthy volunteers of com-
parable age.
Magnetic resonance spectra were obtained from frontal periventricular white matter.
For all subjects, height, body weight, and BMI were assessed. Waist and hip circumference were
measured and waist/hip ratio (W/H ratio) was calculated.
Overnight polysomnography (PSG) to identify sleep apnea was done. Daytime sleepiness was
evaluated by the Epworth Sleepiness Scale. Symptoms of anxiety and depression were measured
with the Hospital Anxiety and Depression Scale (HADS).
Results: N-acetylaspartate-to-creatine (NAA/Cr) and choline-to-creatine (Cho/Cr) ratios were
signiﬁcantly lower in the frontal white matter of obstructive sleep apnea patients when compared
to controls. Absolute concentrations of N-acetylaspartate (NAA) and choline (Cho) were also sig-
niﬁcantly reduced in the frontal white matter of patients with sleep apnea. Statistically signiﬁcant
negative correlations existed between AHI and metabolites concentrations and ratios in patients
with OSAHS. Signiﬁcant positive correlations existed in patients with OSAHS between Hospital
and depression scale for depression (HAD-D) and AHI (r= 0.764, p= 0.001), ODI (r= 0.571,03633634.
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396 H. Gharraf et al.p= 0.026), and ESS (r= 0.644, p= 0.010), respectively. Signiﬁcant positive correlations existed in
patients with OSAHS between Hospital and depression scale for anxiety (HAD-A) and AHI
(r= 0.753, p= 0.001), and ESS (r= 0.537, p= 0.039), respectively.Multivariate Linear regression
model of factors predictive showed AHI as the main predictor factor for choline to creatine ratio in
patients with OSAHS with t= 5.180, at p< 0.001.
Conclusion: OSA patients show abnormal brain metabolites related to neuronal damage due to
intermittent chronic hypoxemia. Anxious and depressive symptoms are highly prevalent in patients
with severe untreated OSAS. The severity of depressive and anxious symptoms may be related to
excessive daytime sleepiness and to nocturnal hypoxemia both of which are strongly correlated
to brain metabolites. AHI seems to be the main predictor factor for choline to creatine ratio in
patients with OSAHS.
ª 2013 The Egyptian Society of Chest Diseases and Tuberculosis. Production and hosting by Elsevier
B.V. Open access under CC BY-NC-ND license.Introduction
Obstructive sleep apnea is a major public health problem
worldwide [1–3]. It is estimated to affect up to 4% of the gen-
eral adult population [4]. It is associated with several conse-
quences including neurocognitive impairment [5]. To date,
the pathophysiology of the cognitive deﬁcits reported in
OSA patients has not been determined.
Repeated sleep apneic episodes may lead to CNS impair-
ment in patients with obstructive sleep apnea (OSA). Excessive
daytime sleepiness and cognitive and emotional deﬁcits are
common daytime symptoms of OSA. Hypoxic brain damage
and fragmentation of sleep are generally thought to be causes
of these deﬁcits [6].
Some researchers argue that excessive daytime somnolence
is the leading cause of the cognitive deﬁcits, while others pro-
pose that nocturnal hypoxemia is the main contributing factor
[4,7].
Magnetic resonance spectroscopy (MRS) is a non-invasive
method, useful for evaluating local metabolic changes in vari-
ous conditions affecting the central nervous system as in pa-
tients with OSAHS [8].
Several studies have shown that executive dysfunction in
OSA patients may persist even after nasal continuous positive
airway pressure (nCPAP) treatment. Cognitive executive func-
tions are associated with speciﬁc prefrontal-subcortical brain
circuits, thus it has been proposed that OSAS may promote
irreversible anoxic brain damage affecting the prefrontal cor-
tex [8].
Subjects and methods
This study included two groups:
Group 1: ﬁfteen (15) patients newly diagnosed with severe
obstructive sleep apnea hypopnea syndrome, and
Group 2: ten (10) healthy volunteers of comparable age.
Fifteen (15) consecutive patients newly diagnosed with se-
vere obstructive sleep apnea hypopnea syndrome who fulﬁlled
the following inclusion criteria were enrolled in this study: ap-
nea/hypopnea index (AHI) >30, age <65 years, Patients’
exclusion criteria were: concomitant metabolic disease (DM,
hypertension), history of stroke, presence of cardiac disease,
neurological disease or history of head injury or CPAP/BiPAP
therapy, presence of other sleep disorders, and presence ofobstructive lung disease. Patients with claustrophobia or
metallic implants were also excluded.
Anthropometric proﬁle
Body weight was recorded in all patients, in erect position
without shoes and wearing only light indoor clothes, height
was measured and body mass index (BMI) was calculated as
body weight/height2 (kg/m2) [9,10].
Waist circumference was measured midway between the
lower rib cage margin and the anterior superior iliac spine.
Hip circumference was measured at the maximum circumfer-
ence of the buttocks, the subject standing with feet placed to-
gether and waist–hip ratio (W–HR) was calculated [11].
Nocturnal sleep studies
All patients underwent overnight polysomnography using
Respironics Alice 5 system (RESPIRONICS, Germany Inc.).
It is a level I device that records parameters such as body posi-
tion, effort (thorax and abdomen), nasal ﬂow (canula and/or
thermistor), snoring (canula and/or microphone), SpO2,
plethysmogram, pulse rate, ECG, CPAP/BiPAP, and PLM
overnight in the hospital. Recordings of at least 5 h were
required to validate the sleep study. The analysis was carried
out automatically and manually. Respiratory events were
scored using standard criteria [12,13].
The apnea hypopnea index (AHI) was deﬁned as the total
number of apneas and hypopneas per hour of sleep. As indices
of nocturnal hypoxemia we considered the oxygen desatura-
tion index (this is the number of times that the oxygen satura-
tion falls by more than 3 or 4 percent per hour of sleep), T90
(the fraction of sleep time spent below an oxygen saturation of
90 percent) and the minimal value recorded during sleep (min-
imal SaO2).
Assessment of daytime sleepiness
The Epworth Sleepiness Scale (ESS) [14,15] was used for
assessing daytime sleepiness. This is a commonly used self-
administered scale with eight items of about how easily the
respondent would fall asleep in different situations. The items
are scored on a 0–3 scale, which are added to give an overall
score of 0–24. Higher scores indicate more sleepiness. ESS
Proton magnetic resonance spectroscopy of brain 397score 2–10 is considered ‘normal’ and >10 indicative of path-
ological sleepiness.
Assessment of anxiety and depression
Symptoms of anxiety and depression were measured with the
Hospital Anxiety and Depression Scale (HADS) [16]. The
HADS is a validated and reliable psychological measure widely
used in both hospitalized and primary care patients with
chronic diseases. The HADS is divided into an anxiety subscale
(HADS-A) and a depression subscale (HADS-D) both contain-
ing seven items, rated 0–3, giving a possible maximum score for
anxiety and depression of 21. The scores range from 0 to 21 for
each subscale, with a score of 0–7 denoting a non case, 8–10 a
possible case, and 11 or higher a probable case.
Neuroimaging
1H MR spectroscopy was carried at 1.5 Tesla (AVANTO,
Siemens, Germany) using a phased array head coil. Prior to
performing 1H MR spectroscopy, multislice T1-weighted
images in the axial, coronal and sagittal planes of the whole
brain were acquired using a standard spin-echo pulse sequence.
These images were then used to select the region of interest for
performing the MR spectroscopy.
Multi-voxel proton MR spectra were recorded using the
PRESS pulse sequence (Fig. 10). Absolute concentration of
metabolites (NAA, Cho and Cr) and ratios (NAA/Cr and
Cho/Cr) at prefrontal cortex and frontal periventricular white
matter were recorded. The concentration of metabolites was
expressed as milli moles per liter (mmol/l).
Statistical analysis
Data were fed to the computer using IBM SPSS software pack-
age version 20.0.
Qualitative data were described using number and percent.
Comparison between different groups regarding categorical
variables was tested using the Chi-square test. When more
than 20% of the cells have expected count less than 5, correc-
tion for chi-square was conducted using the Fisher’s Exact test
or Monte Carlo correction.
The distributions of quantitative variables were tested for
normality using the Shapiro–Wilk test and D’Agstino test, also
the Histogram and QQ plot were used for vision test. If it re-
veals normal data distribution, parametric tests were applied.Table 1 Baseline characteristics of the study groups.
Patients with OSAHS (n= 15)
Age (years) 48.07 ± 6.92
Gender, n (%)
Male 11 (73.3)
Female 4 (26.7)
BMI (kg/m2) 47.31 ± 13.53
Waist–hip ratio 1.03 ± 0.06
ESS 17.73 ± 2.46
Results are expressed as mean ± standard deviation unless otherwise spe
mass index; ESS, Epworth Sleepiness Scale.
* Statistically signiﬁcant at p 6 0.0If the data were abnormally distributed, non-parametric tests
were used.
Quantitative data were described using mean and standard
deviation for normally distributed data while abnormally dis-
tributed data were expressed using median, minimum and
maximum.
For normally distributed data, comparison between two
independent population were done using the independent t-
test.
For abnormally distributed data, Mann–Whitney Test (for
data distribution that was signiﬁcantly deviated from normal)
was used to analyze two independent population.
Signiﬁcance test results are quoted as two-tailed probabili-
ties. Signiﬁcance of the obtained results was judged at the 5%
level.Results
A total of 25 subjects underwent overnight polysomnography
and had early morning 1H MRS of the brain. Of these, the ap-
neic group consisted of 15 patients who had AHI >30/h (fe-
male 4, male 11) while the remaining 10 were non-apneic with
AHI <5/h (female 3, male 7). The mean age of apneic and
non-apneic was 48.07 ± 6.92 and 49.10 ± 7.64 year, respec-
tively. The apneic patients had a statistically signiﬁcantly high-
er mean BMI compared to non-apneic subjects (47.31 ± 13.53
and 26.20 ± 2.12 kg/m2, respectively, p< 0.001. The waist–
hip ratio was signiﬁcantly higher (P< 0.05) in apneic patients
as compared to non apneic (Table 1).
Seven patients with OSAHS (46.7%) had an anxiety score
P11 (probable anxiety), and 15 patients with OSAHS that is
to say all of the studied patients (100%) had a depression score
P11 (probable depression). Whereas patients without OSAHS
did not show evidence of anxiety or depression (Table 2)
(Fig. 1).
The mean Epworth Sleepiness Scale (ESS) value in patients
with OSAHS (17.73 ± 2.46) was statistically signiﬁcantly
higher (P< 0.001) as compared to patients without OSAHS
(3.40 ± 1.17). The AHI was statistically signiﬁcantly higher
(P< 0.001) in patients with OSAHS (65.47 ± 20.34 events/
h) as compared to patients without OSAHS (2.70 ± 1.16
events/h). The average SaO2 and minimum SaO2 were statisti-
cally signiﬁcantly lower in patients with OSAHS compared to
patients without OSAHS (86.40 ± 6.20, 94.0 ± 2.67%,
respectively, p= 0.001 and 64.27 ± 10.10, 89.90 ± 2.77%,
respectively, p< 0.001). t90 was statistically signiﬁcantlyPatients without OSAHS (n= 10) p
49.10 ± 7.64 0.729
7 (70.0) 1.000
3 (30.0)
26.20 ± 2.12 <0.001*
0.98 ± 0.02 0.010*
3.40 ± 1.17 <0.001*
ciﬁed. Deﬁnition of abbreviations: n, number of patients; BMI, body
Table 2 Comparison of the HAD anxiety and depression scales in the patients and control group.
Patients with OSAHS (n= 15) Patients without OSAHS (n= 10) p
Anxiety 11.33 ± 2.55 4.70 ± 2.36 <0.001*
Normal (0–7) 0 (0.0) 9 (90.0)
Borderline (8–10) 8 (53.3) 1 (10.0) <0.001*
Abnormal (11–21) 7 (46.7) 0 (0.0)
Depression 16.27 ± 2.34 5.80 ± 1.14 <0.001*
Normal (0–7) 0 (0.0) 9 (90.0)
Borderline (8–10) 0 (0.0) 1 (10.0) <0.001*
Abnormal (11–21) 15 (100.0) 0 (0.0)
HADS-A: Hospital anxiety and depression subscale for anxiety.
HADS-D: Hospital anxiety and depression subscale for depression.
* Statistically signiﬁcant at p 6 0.05. p: p value for Student t-test.
Figure 1 Comparison of the HAD anxiety and depression scales in the patients and control groups.
Table 3 Comparison of polysomnography parameters between the study groups.
Patients with OSAHS (n= 15) Patients without OSAHS (n= 10) Test of sig.
Average SaO2, (%) 86.40 ± 6.20 94.0 ± 2.67 0.001
*
Minimum SaO2, (%) 64.27 ± 10.10 89.90 ± 2.77 <0.001
*
t90 min 0.55 ± 0.28 0.02 ± 0.03 <0.001*
AHI events/h- 65.47 ± 20.34 2.70 ± 1.16 <0.001*
ODI/h 50.80 ± 19.55 0.70 ± 0.67 <0.001*
ESS score 17.73 ± 2.46 3.40 ± 1.17 <0.001*
Results are expressed as mean ± standard deviation unless otherwise speciﬁed. Deﬁnition of abbreviations: ESS: Epworth Sleepiness Scale,
AHI: apnea hypopnea index, ODI: oxygen desaturation index, t90: fraction of sleep time spent below an oxygen saturation of 90 percent, SaO2:
arterial oxygen saturation.
* Statistically signiﬁcant at p 6 0.05. p: p value for Student t-test.
398 H. Gharraf et al.higher in patients with OSAHS (0.55 ± 0.28) compared to pa-
tients without OSAHS (0.02 ± 0.03) with p< 0.001. The
mean value of ODI in patients with OSAHS (50.80 ± 19.55)
was statistically signiﬁcantly higher (p< 0.001) as compared
to patients without OSAHS (0.70 ± 0.67) (Table 3).Patients with OSA had signiﬁcantly decreased NAA and
Cho absolute concentrations (Fig. 2) in frontal white matter
compared to controls (37.0 ± 4.19 versus 47.0 ± 1.70,
p< 0.001 and 23.40 ± 0.63 versus 27.50 ± 1.51, p< 0.001,
respectively). In comparison to the control group, patients
Figure 2 Comparison of absolute metabolite concentrations between patients with obstructive sleep apnea (OSA) and controls.
Figure 3 Comparison of metabolite ratios between patients with obstructive sleep apnea (OSA) and controls.
Table 4 Comparison of absolute metabolite concentrations and metabolite ratios between patients with obstructive sleep apnea
(OSA) and controls.
Patients with OSAHS (n= 15) Patients without OSAHS (n= 10) Test of sig.
Choline (Cho) 23.40 ± 0.63 27.50 ± 1.51 <0.001*
N-acetylaspartate (NAA) 37.0 ± 4.19 47.0 ± 1.70 <0.001*
Choline to creatine (Cho/Cr) 0.99 ± 0.08 1.17 ± 0.03 <0.001*
N-acetylaspartate to creatine (NAA/Cr) 1.13 ± 0.13 2.08 ± 0.15 <0.001*
* Statistically signiﬁcant at p 6 0.05.
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Figure 5 Correlation between HAD-D with different metabo-
lites in patients with OSAHS.
400 H. Gharraf et al.with OSAHS showed a signiﬁcant reduction in the Cho/Cr
(1.17 ± 0.03 versus 0.99 ± 0.08 respectively) and NAA/Cr ra-
tios (2.08 ± 0.15 versus 1.13 ± 0.13 respectively) in frontal
white matter (Fig. 3) (Table 4).
Correlations (Figs. 4–9)
Statistically signiﬁcant negative correlations existed between
AHI and metabolite concentrations and ratios in patients with
OSAHS as follows.
- There was a negative correlation between apnea hypopnea
index (AHI) and choline in frontal white matter of patients
with OSAHS (r= 0.799, p< 0.001).
- There was a negative correlation between apnea hypopnea
index (AHI) and N-acetylaspartate in frontal white matter
of patients with OSAHS (r= 0.693*, p= 0.004).
- AHI in patients with OSAHS signiﬁcantly inversely corre-
lated with choline to creatine ratio (r= 0.878,
p< 0.001), and also inversely with N-acetylaspartate to
creatine ratio (r= 0.782, p= 0.001).
ODI in patients with OSAHS signiﬁcantly inversely corre-
lated with choline to creatine ratio (r= 0.590, p= 0.020).
Hospital and depression scale for depression (HAD-D) sig-
niﬁcantly inversely correlated with choline (r= -0.655,
p= 0.008), choline to creatine ratio (r= 0.618, p= 0.014),
and N-acetylaspartate to creatine ratio (r= 0.596,
p= 0.019) in patients with OSAHS.
Hospital and depression scale for anxiety (HAD-A) signif-
icantly inversely correlated with choline (r= 0.752,
p= 0.001), and also inversely with N-acetylaspartate
(r= 0.547, p= 0.035) in patients with OSAHS.
Signiﬁcant positive correlations existed in patients with
OSAHS between Hospital and depression scale for depression
(HAD-D) and AHI (r= 0.764, p= 0.001), ODI (r= 0.571,
p= 0.026), and ESS (r= 0.644, p= 0.010), respectively.
Signiﬁcant positive correlations existed in patients with
OSAHS between Hospital and depression scale for anxiety
(HAD-A) and AHI (r= 0.753, p= 0.001), and ESS
(r= 0.537, p= 0.039), respectively.0
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Figure 4 Correlation between AHI events/h- with different
metabolites in patients with OSAHS.Multivariate Linear regression model of factors predictive
showed AHI as the main predictor factor for choline to
creatine ratio in patients with OSAHS with t= 5.180, at
p< 0.001.
Discussion
Frontal lobe white matter lesions are known to be associated
with cognitive executive dysfunction. This may offer an expla-
nation for the sometimes irreversible cognitive deﬁcits associ-
ated with sleep apnea [9].
Decreased NAA in the frontal white matter of OSA
patients indicates axonal loss and/or dysfunction. The deep
white matter, where metabolic impairment seems to be selec-
tively affected in patients with OSAS [9].
An explanation is that the arterial supply of the deep white
matter is not sufﬁcient to compensate for the decreased and
ﬂuctuating cerebral perfusion and the impaired cerebral vascu-
lar autoregulation reported in OSA patients [5].
M. Alchanatis et al., stated that the results of their study
demonstrate that severe obstructive sleep apnea syndrome
can promote axonal loss or dysfunction, as well as myelin
metabolism impairment in the frontal periventricular white
matter. These lesions are in the territory of crucial frontal-sub-
cortical circuits and they could be associated with the, some-
times irreversible, cognitive executive deﬁcits reported in
obstructive sleep apnea patients [9].
Kamba, Inoue, Higami, et al., concluded that their MRS
ﬁndings indicate that a signiﬁcant relation exists between
AHI and the degree of metabolic impairment in cerebral white
matter. Magnetic resonance spectroscopy may be useful for
evaluation of CNS impairment in patients with OSA [5].
NAA was found to be negatively correlated with AHI in the
left frontal region, indicating that higher the AHI, lower is the
concentration of NAA, indicating possible neuronal damage
of the brain. Similar negative correlation was reported by Sar-
chielli et al. [10] between AHI and NAA/Cr ratio in the frontal
regions of the brain of OSA patients [6].
Patients with OSA frequently have a combination of vascu-
lar risk factors, including hypertension, diabetes mellitus,
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Figure 7 Correlation between HAD-A with choline and
N-acetylaspartate concentrations in patients with OSAHS.
Proton magnetic resonance spectroscopy of brain 401hyperlipidemia and central obesity. All these factors are asso-
ciated with an increased risk of stroke and could possibly pro-
mote brain metabolic impairment. Nevertheless, in our study,
the group of patients with OSA studied was selected without a
medical history of cardiac disease or cardiovascular risk fac-
tors in order to abolish the effects of confounding factors on
brain metabolites [9].
We found that in comparison to the control group, patients
with OSAHS showed a signiﬁcant reduction in the Cho/Cr
(1.17 ± 0.03 versus 0.99 ± 0.08, respectively) and NAA/Cr ra-
tios (2.08 ± 0.15 versus 1.13 ± 0.13, respectively) in frontal
white matter. Patients with OSA had signiﬁcantly decreased
NAA and Cho absolute concentrations in frontal white matter
compared to controls (37.0 ± 4.19 versus 47.0 ± 1.70,
p< 0.001 and 23.40 ± 0.63 versus 27.50 ± 1.51, p< 0.001,
respectively [9]).
The results demonstrated a signiﬁcant decrease in NAA/Cr
and Cho/Cr ratios, as well as a reduction in absolute concen-
trations of NAA and Cho, in the frontal white matter of
patients with OSA when compared to controls. This ﬁnding
suggests that OSAS may promote brain metabolic impairment
even in the absence of cardiovascular co-morbidities.
When compared to our study, previous studies applying
MRS with chemical shift imaging have demonstrated a de-
crease in the NAA/Cho ratio in the posterior periventricular
white matter [5] and lactate production in the Centrum semio-
vale of patients with OSA during sleep, indicating that hypoxia
is causing anaerobic glycolysis [12]. Absolute concentrations
were not calculated in these studies, so it is not clear if the de-
creased ratio was due to a decrease in NAA and/or an eleva-
tion in Cho [9].
In our study, statistically signiﬁcant negative correlations
existed between AHI and metabolite concentrations as well
as ratios in patients with OSAHS.
In agreement to our ﬁndings, a recent study, using com-
puted tomography, demonstrated that white matter disease
severity in patients with acute stroke and OSAS correlated
independently with AHI [13]. One possible explanation is that
the arterial supply of the deep white matter is not sufﬁcient to
compensate for the decreased and ﬂuctuating cerebral perfu-
sion and the impaired cerebral vascular autoregulation that
have been reported in OSA patients [14,15]. In fact, the arterial0.0
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Figure 6 Correlation between HAD-D and choline to creatine
ratio in patients with OSAHS.networks of the deep white matter, so-called internal border
zone, are terminals without collaterals or anastomoses [9]. This
perspective was supported in our study by the Multivariate
Linear regression model of factors predictive that showed
AHI as the main predictor factor for choline to creatine ratio
in patients with OSAHS with t= 5.180, at p< 0.001.
Another study done by Alchanatis, Deligiorgis, Zias dem-
onstrated the decrement of Cho in the frontal white matter
of patients with OSA. It has been suggested that decreased
in vivo Cho levels indicate loss of myelin lipids or phospholipid
metabolism dysfunction [17].
These results are in agreement with the report of Shim et al.
[16]. These investigators found a reduction in NAA, Cr and
Cho concentrations in the parietal white matter of COPD pa-
tients with resting normoxemia and nocturnal desaturation, a
respiratory proﬁle similar to OSAS.
A previous study has demonstrated a decrease in Cho
metabolites as a consequence of brief ischemic episodes in an
experimental animal model [17].
Nevertheless, if chronic hemodynamic impairment was the
sole pathogenic factor related to OSA, one would expect an
elevation of Cho due to gliosis and myelin breakdown [17].0
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Figure 8 Correlation between AHI events/h- and depression
anxiety scales in patients with OSAHS.
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Figure 9 Correlation between ESS and depression anxiety scales
in patients with OSAHS.
402 H. Gharraf et al.It was suggested that a possible interpretation for the Cho dec-
rement is that OSA does not promote gliosis but induces brain
metabolic impairment through a unique combination of ﬂuctu-
ating hemodynamic impairment, sleep fragmentation and
intermittent hypoxia [17].
Dorsey et al. [18] found an increase in glycerophosphocho-
line concentration in healthy volunteers after the recovery
night, following a night of sleep deprivation [18]. In a study
done by Alchanatis, Deligiorgis, Zias et al., although the pa-
tients did not have severe sleepiness, ESS score is correlated
with NAA/Cho ratio, but only in the posterior white matter.
However, in our study, no correlation was illustrated between
ESS and metabolite concentrations in the brain of patients
with OSA.
Frontal white matter lesions could be associated with the
neuropsychological deﬁcits that complicate OSAS. PatientsFigure 10 (a–b) Proton MR spectrum from the frontal white matte
(right and left, respectively). The abbreviations shown in ﬁgure corres
They show low levels of choline and NAA.with OSAS frequently have mild impairment in attention/con-
centration, memory and, in particular, executive functions,
such as problem solving, planning of goal-oriented behavior
and mental ﬂexibility, which are sometimes irreversible, even
after nCPAP treatment [8].
In the study done by Alchanatis, Deligiorgis, Zias et al. and
also in our study, no metabolic impairment was studied in the
examined prefrontal cortex, but it was demonstrated that pa-
tients with severe OSAS have metabolic impairment in the
frontal white matter. It is, therefore, suggested that these ﬁnd-
ings may offer an explanation for the speciﬁc pattern of cogni-
tive deﬁcits frequently reported in OSA patients, as it is well
known that anterior white matter lesions can induce executive
dysfunction by interrupting prefrontal-subcortical circuits.
An important limitation to our study is the lack of neuro-
psychological measures in the examined patients, although it
is well documented that frontal lobe-mediated executive func-
tions are usually impaired in patients with severe OSAS [8].
A second limitation is that, because only patients with se-
vere OSA were included, there were not enough variances in
the respiratory parameters that could predict the metabolic
changes.
An important consideration is about the effect of aging on
brain metabolism. MRS studies on the effect of aging on brain
metabolites are often discrepant. Results of quantitative MRS
studies vary from increased Cr and Cho levels to unchanged or
decreased NAA levels and lack of any signiﬁcant change [19].
In our study, both patient and control groups were selected to
be age matched to avoid the confounding effect of age on brain
metabolites between both groups that is why detailed assess-
ment of aging on brain metabolism was not done.
In our study, seven patients with OSAHS (46.7%) had an
anxiety score P11 (probable anxiety), and 15 patients with
OSAHS that is to say all of the studied patients (100%) had
a depression score P11 (probable depression). Signiﬁcant
positive correlations also existed in patients with OSAHSr of an apneic patient. The insert shows the voxel position in the
pond to: NAA (N-acetylaspartate); Cr (Creatine); Cho (Choline).
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(HAD-D) and AHI(r= 0.764, p= 0.001), ODI(r= 0.571,
p= 0.026), and ESS(r= 0.644, p= 0.010), respectively.
We found that the Hospital and depression subscale for
depression (HAD-D) signiﬁcantly inversely correlated with
choline (r= 0.655, p= 0.008), choline to creatine ratio
(r= 0.618, p= 0.014), N-Acetylaspartate to choline ratio
(r= 0.596, p= 0.019) in patients with OSAHS. We also
found that the Hospital and depression subscale for anxiety
(HAD-A) signiﬁcantly inversely correlated with choline
(r= 0.752, p= 0.001), and also inversely with N-acetylas-
partate (r= 0.547, p= 0.035) in patients with OSAHS.
This study has its own limitations; ﬁrst, the unequal num-
ber of males and females, as the gender of subjects may have
a signiﬁcant impact on mood; since women are more vulnera-
ble to mood alterations. Also, it is important to take note of
the limitations of mood scales, which are not proper diagnostic
tools for the detection of depression or anxiety; they only rep-
resent depressive and anxious symptoms, however diagnosis of
the clinical entity requires a psychiatric consultation.
In a study done by Daabis and Gharraf [20] anxious and
depressive symptoms were highly prevalent in patients with
moderate to severe untreated obstructive sleep apnea. The
severity of depressive symptoms might have been more related
to excessive daytime sleepiness than to nocturnal hypoxemia.
This last perspective gained support from their ﬁnding that
EDS as measured by the Epworth Sleepiness Scale (ESS) was
the main predictor for the HAD depression score in the linear
regression analysis (p= 0.001).
Therefore, in clinical practice we think it is feasible to be alert
to psychiatric symptoms in patients with OSAS and routine
screening with instruments like the HAD scale should be
encouraged, to improve QOL and optimize diagnosis and ther-
apy in these patients. Future research is needed to investigate the
causal relationship between psychiatric symptoms and OSAS,
as well as the appropriate treatment for these comorbidities.
In conclusion, the results of this study demonstrate that se-
vere obstructive sleep apnea syndrome can promote axonal
loss or dysfunction, as well as myelin metabolism impairment
in the frontal periventricular white matter. These lesions are in
the territory of crucial frontal-sub cortical circuits and they
could be associated with the, sometimes irreversible, cognitive
executive deﬁcits reported in obstructive sleep apnea patients.
Further studies are needed to conﬁrm whether there is a direct
correlation between frontal metabolic dysfunction and cogni-
tive impairment in obstructive sleep apnea patients, and to
examine the reversibility of the spectroscopic abnormalities
after nasal continuous positive airway pressure treatment.
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